1/29/2008

Cambridge, Mass.-based Alnylam Pharmaceuticals has secured a patent from the U.K. Patent Office for 32 claims covering molecules that affect RNA interference. The patent allows Alnylam to expand its list of potential RNAi-related treatments.

Related Summaries